Shengen Bio's siRNA Candidate SGB-7342 Enters Phase 1 Clinical Trial in China for Treatment of Overweight and Obesity

On January 13, SANEGENEBIO announced that its self-developed small interfering RNA (siRNA) candidate drug SGB-7342 completed the first dosing of a subject in a Phase 1 clinical study in China for the treatment of obesity at the First Hospital of Jilin University. This randomized, double-blind, placebo-controlled, single ascending dose Phase 1 clinical study aims to evaluate SGB-7342 in...Overweight and obese patientsSafety, tolerability, pharmacokinetics, and pharmacodynamics in China.

SGB-7342 is aTargeted Inhibin βE Subunit (INHBE)An siRNA candidate drug for the treatment of obesity, developed using SANEGENEBIO's proprietary GalNAc conjugation delivery technology and chemical modification technology. This platform technology has demonstrated clinical application potential in Phase 1 clinical trials of multiple siRNA drugs under development by the company.

SGB-7342 specifically silences through RNAi technologyINHBEThe expression of the gene, which in turn reduces the level of its encoded protein Activin E, effectively inhibits the activity of downstream signaling pathways related to lipid metabolism and energy expenditure.Preclinical studies have shown that SGB-7342 can potently and durably silenceINHBEExpression, significant weight loss and reduction in fat mass, while maintaining muscle mass, and demonstrating good safety and tolerability.

References:
[1]SANEGENEBIO's SGB-7342 (INHBE siRNA) Completes First Dosing in Subjects. From https://mp.weixin.qq.com/s/R7me4bXm2Ur8NZp_jseyJw

Disclaimer: This article is for the purpose of information exchange only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.